Introduction
============

Stevens--Johnson syndrome (SJS) and some toxic epidermal necrolysis (TEN) are acute inflammatory vesiculobullous reactions of the skin and mucous membranes, including the ocular surface, oral cavity and genitals, which are often associated with inciting drugs and infectious agents.^[@bib1; @bib2; @bib3; @bib4; @bib5; @bib6]^ These reactions carry high mortality rates of 3% for SJS and 27% for TEN,^[@bib7]^ and surviving patients often experience severe sequelae such as vision loss due to severe ocular surface complications (SOC),^[@bib8]^ although incidences are rare (one to six cases per million persons).^[@bib6],[@bib9]^

We previously reported that *PTGER3* (prostaglandin E receptor 3 (subtype EP3)) SNPs were associated with SJSTEN with SOC. Our genome-wide association study showed associations between six single-nucleotide polymorphisms (SNPs) in the prostaglandin E receptor 3 gene (*PTGER3*) and SJS/TEN with SOC,^[@bib4]^ and our subsequent analysis using the DigiTag2 assay showed that 20 of the 38 SNPs of *PTGER3* were associated with SJS/TEN with SOC.^[@bib10]^

We also documented that approximately 80% of our SJS/TEN patients had taken cold medicines within several days before disease onset and accordingly designated them cold medicine related-SJS/TEN (CM-SJS/TEN) patients.^[@bib1]^ Moreover, we reported that *HLA-A\*02:06* with *TLR3* polymorphisms exerted more than additive effects in SJS/TEN with SOC.^[@bib11]^ We also reported that *HLA-A\*02:06* was strongly associated with CM-SJS/TEN with SOC in Japanese individuals^[@bib1]^ and was significantly associated with CM-SJS/TEN with SOC in Korean individuals.^[@bib2]^

In this study, we focused on CM-SJS/TEN with SOC and analyzed the association with *PTGER3* SNPs. We also asked whether there is an interactive effect between *PTGER3* SNPs and *HLA-A\*02:06* in not only Japanese but also Korean populations.

Materials and methods
=====================

Patients
--------

This study was approved by the institutional review boards of Kyoto Prefectural University of Medicine and the University of Tokyo as well as by the institutional review boards of Seoul National University College of Medicine, Yonsei University College of Medicine, Chonnam National University Medical School and College of Medicine and the Catholic University of Korea.

All experimental procedures were conducted in accordance with the principles of the Declaration of Helsinki. The purpose of the research and the experimental protocols were explained to all the participants; all gave their written informed consent before their participation in this study.

The diagnosis of SJS/TEN by the Japanese and Korean ophthalmologists was based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions and the involvement of at least two mucosal sites including the ocular surface.^[@bib1],[@bib2]^ Because ophthalmologists usually encounter SJS/TEN patients in the chronic rather than the acute stage, many of our patients had developed SJS/TEN many years before their recruitment for this study.

We defined patients with severe ocular complications (SOC) as patients who manifested pseudomembranes and ocular surface (cornea and/or conjunctiva) epithelial defects in the acute stage, and as ones with ocular sequelae such as severe dry eye, symblepharon, trichiasis and conjunctival invasion into the cornea in the chronic stage.^[@bib1],[@bib2]^

In this study, we focused on cold medicine-related SJS/TEN (CM-SJS/TEN) that may have been elicited by cold medicines such as multi-ingredient cold medications and nonsteroidal anti-inflammatory drugs (NSAIDs). All the patients included in this study had taken cold medicines (e.g., NSAIDs, multi-ingredient cold medications) for symptoms of common cold a few to several days before disease onset.^[@bib1],[@bib2]^ They were designated CM-SJS/TEN patients, although not all were able to name the specific drugs used. We also focused on SJS/TEN patients with SOC because the genetic predisposition might be different between SJS/TEN with and without SOC.^[@bib1]^

Samples from 132 patients with CM-SJS/TEN with SOC were collected at Kyoto Prefectural University of Medicine. Of these patients, 51 were male and 81 were female; their ages ranged from 6 to 92 years (mean 42.4±17.4 (s.d.) years). The age at SJS/TEN onset ranged from 1 to 70 years (mean 24.7±16.2 years). Some of the patients could not recall the specific drug(s) they used. The controls were 221 healthy Japanese volunteers recruited by Kyoto Prefectural University of Medicine. They consisted of 89 males and 132 females; their ages ranged from 11 to 77 years (mean 35.6±11.1 years). Some of the CM-SJS/TEN patients and some of the controls had been included in our earlier studies.

Samples from 30 Korean patients with CM-SJS/TEN with SOC were collected at Seoul National University College of Medicine, Yonsei University, Chonnam National University and the Catholic University of Korea. These patients consisted of 11 males and 19 females, ranging in age from 4 to 71 years (mean 35.2±18.9 years). Their ages at the onset of SJS/TEN ranged from 3 to 63 years (mean 23.7±16.3 years). Healthy Korean volunteers ranging from 16 to 85 years old (*n*=120; 48 males and 72 females; mean age 38.1±15.6 years) served as the controls. Some of the CM-SJS/TEN patients and some of the controls had been included in our earlier studies.

Genomic DNA from the peripheral blood of Japanese patients and controls was isolated by SRL (Tokyo, Japan). The PAXgene blood DNA kit (Qiagen, Hilden, Germany) was used to extract DNA from whole peripheral blood of Korean patients and controls.

SNP genotyping
--------------

In the TaqMan SNP genotyping assay, PCR amplification was performed in a 10-μl reaction mixture containing 1 μl of genomic DNA, 5.0 μl of TaqMan GTXpress master mix (Applied Biosystems, Foster, CA, USA), and 40×TaqMan SNP genotyping assay probe (Applied Biosystems) for each SNP. The QPCR thermal cycling program was 95 °C for 20 s, followed by 50 cycles of 95 °C for 3 s and 60 °C for 20 s on a step-one plus system (Applied Biosystems).

In the DigiTag2 assay,^[@bib10],[@bib12]^ multiplex PCR was performed in 10 μl multiplex PCR buffer containing 25 ng genomic DNA, 25 nM each multiplex primer mix, 200 μM each dNTP, 2.25 mM MgCl~2~ and 0.4 U KAPA2G Fast HotStart DNA polymerase (Kapa Biosystems, Boston, MA, USA). Cycling was performed at 95 °C for 3 min, followed by 40 cycles of 95 °C for 15 s and 68 °C for 2 min.

A chi-square test was applied to a two-by-two contingency table for the allele frequency and the dominant and recessive models.

HLA-A genotyping
----------------

For HLA-A genotyping, we performed PCR amplification followed by hybridization with sequence-specific oligonucleotide probes (PCR-SSO) using commercial bead-based typing kits (WAK Flow, Wakunaga, Hiroshima, Japan) as described elsewhere.^[@bib1],[@bib2]^

Results
=======

Associations with PTGER3 SNPs in Japanese population
----------------------------------------------------

In Japanese patients, 7 of 18 SNPs previously reported to be associated with SJS/TEN were significantly associated with CM-SJS/TEN with SOC after Bonferroni correction ([Table 1a](#tbl1){ref-type="table"}). *PTGER3* SNP rs1327464 (G versus A) was most significantly associated with CM-SJS/TEN with SOC; the odds ratio (OR) for the major allele was 0.232 (*P*=7.92×10^−10^).

Interaction between HLA-A\*02:06 and *PTGER3* gene SNPs in Japanese population
------------------------------------------------------------------------------

As we had found earlier that *HLA-A\*02:06* was strongly associated with CM-SJS/TEN with SOC in the Japanese,^[@bib1]^ we then looked for interactive effects between these seven SNPs of the *PTGER3* gene and *HLA-A\*02:06* ([Supplementary Table 1](#xob1){ref-type="supplementary-material"}). We found an interaction with additive effects between *HLA-A\*02:06* and the high-risk genotypes *PTGER3* rs1327464 GA or AA (OR=10.8, *P*=2.56×10^−7^; [Table 1b](#tbl1){ref-type="table"}).

Associations with PTGER3 SNPs in Korean population
--------------------------------------------------

We then analyzed those seven SNPs using Korean samples because we had detected the same association between *HLA-A\*02:06* and CM-SJS/TEN with SOC in Korean patients.^[@bib2]^ Although the number of Korean cases (*n*=30) was small, we again found a significant association between CM-SJS/TEN with SOC and *PTGER3* SNP rs1327464 (GG versus GA+AA, OR=0.246, *P*=0.00101; [Table 2a](#tbl2){ref-type="table"}) but not with other SNPs ([Supplementary Table 2](#xob1){ref-type="supplementary-material"}).

Interaction between HLA-A\*02:06 and the *PTGER3* SNP in Korean population
--------------------------------------------------------------------------

When we tested for possible interactive effects between the SNPs of the *PTGER3* gene and *HLA-A\*02:06,* we detected an additive effect (*HLA-A\*02:06* with *PTGER3* rs1327464 risk genotypes GA or AA; OR=14.2, *P*=5.58×10^−6^; [Table 2b](#tbl2){ref-type="table"}).

Discussion
==========

We now document that several SNPs of *PTGER3* are significantly associated with CM-SJS/TEN with SOC and that the association with *PTGER3* SNP rs1327464 (cases, *n*=131; controls, *n*=219, OR (major allele)=0.232, *P*=7.92×10^−10^) is much stronger than that we previously reported regarding SJS/TEN with SOC, which included not only cold medicine-related but also other drug-related cases (cases, *n*=116; controls, *n*=221; OR (major allele)=0.46, *P*=0.0043).^[@bib10]^ The association with the other six SNPs was the same as or slightly stronger than we previously reported. This result might suggest that CM-SJS/TEN with SOC is a purer phenotype than SJS/TEN with SOC.

Earlier, we reported that HLA-A\*02:06 is significantly associated with CM-SJS/TEN with SOC in Japanese and Korean populations;^[@bib2]^ in this study, we also found a significant association between HLA-A\*02:06 and Japanese or Korean CM-SJS/TEN with SOC ([Supplementary Table 3](#xob1){ref-type="supplementary-material"}). We also reported that *HLA-A\*02:06* with *TLR3* polymorphisms exerted more than additive effects in SJS/TEN with SOC.^[@bib11]^ Our current study shows that *HLA-A\*02:06* with *TLR3* SNP rs3775296 T/T also exerts more than additive effects in CM-SJS/TEN with SOC ([Supplementary Table 4](#xob1){ref-type="supplementary-material"}). *HLA-A\*02:06* with *PTGER3* rs1327464 GA/AA also exerts an additive effect in CM-SJS/TEN with SOC. After removing samples with both *HLA-A\*02:06* and *TLR3* SNP rs3775296 T/T, the additive effect between *HLA-A\*02:06* and *PTGER3* rs1327464 GA/AA persisted in CM-SJS/TEN with SOC ([Supplementary Table 5](#xob1){ref-type="supplementary-material"}; OR=10.6, *P*=4.34×10^−7^), suggesting that these interactions are independent of each other. In the Japanese population, although HLA-A\*02:06 alone showed OR=5.46 and *P*=1.39×10^−11^, and *PTGER3* rs1327464 GA/AA alone showed OR=4.48 and *P*=1.90×10^−8^, the combination of *HLA-A\*02:06* and *PTGER3* rs1327464 GA/AA showed a higher OR (OR=10.8, *P*=2.56×10^−7^) than each allele alone. Moreover, in the Korean population, the combination of *HLA-A\*02:06* and *PTGER3* rs1327464 GA/AA showed a higher OR (OR=14.2, *P*=5.58×10^−6^) than each allele alone, although HLA-A\*02:06 alone showed OR=2.50 and *P*=0.0412, and *PTGER3* rs1327464 GA/AA alone showed OR=4.07 and *P*=0.00101. These findings might show that using the combination of these two polymorphisms could improve genetic testing compared with using only one susceptibility gene.

In the Japanese population, combined genotyping for *HLA-A\*02:06, TLR3* rs3775296 T/T and *PTGER3* rs1327464 GA or AA may help to predict the risk for CM-SJS/TEN with SOC.

On the basis of our previous and current observations, we suggest that, in addition to microbial infections and cold medicines, the combination of multiple gene polymorphisms and their interactions contribute strongly to the onset of CM-SJS/TEN with SOC.

In conclusion, this study clarified the following: (1) SNPs of *PTGER3* are significantly associated with CM-SJS/TEN with SOC, and the association with *PTGER3* SNP rs1327464 (OR (major allele)=0.232, *P*=7.92×10^−10^) is much stronger than that we previously reported regarding SJS/TEN with SOC, suggesting that CM-SJS/TEN with SOC might be a purer phenotype than SJS/TEN with SOC and (2) in CM-SJS/TEN with SOC, *HLA-A\*02:06* with *PTGER3* rs1327464 GA/AA also exerts an additive effect.
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###### Japanese CM-SJS/TEN with SOC patients

  *a. Association with PTGER3 SNPs*                                                                                                      
  ----------------------------------- ---- ----- ---------------- ---------------- -------------------------- -------------------------- -----------------------------
  rs7555865                           11    C/C  56/132 (42.4)    105/219 (47.9)             0.106                      0.315                       0.0772
                                      12    C/T  55/132 (41.7)    93/219 (42.5)                                                                         
                                      22    T/T  21/132 (15.9)    21/219 (9.59)                                                                         
                                                                                                                                                        
  rs17131450                          11    C/C  97/132 (73.5)    194/221 (87.8)      **1.22×10**^**−4**^        **6.36×10**^**−4**^                0.0190
                                      12    C/T  30/132 (22.7)    26/221 (11.8)       **2.20×10**^**−3**^             **0.0114**                     0.342
                                      22    T/T  5/132 (3.79)     1/221 (0.452)     **0.379** (0.228--0.630)   **0.386** (0.221--0.674)      0.115 (0.0133--0.999)
                                                                                                                                                        
  rs5702                              11    C/C  87/131 (66.4)    109/221 (49.3)             0.0228              **1.81×10**^**−3**^                 0.628
                                      12    C/T  32/131 (24.4)    95/221 (43.0)              0.410                    **0.0325**                        
                                      22    T/T  12/131 (9.16)    17/221 (7.69)        1.52 (1.06--2.17)        **2.03** (1.30--3.18)                   
                                                                                                                                                        
  rs1325949                           11    A/A  91/132 (68.9)    105/221 (47.5)      **1.94×10**^**−3**^        **8.86×10**^**−5**^                 0.950
                                      12    A/G  30/132 (22.7)    98/221 (44.3)            **0.0349**            **1.59×10**^**−3**^                    
                                      22    G/G  11/132 (8.33)    18/221 (8.14)      **1.77** (1.23--2.55)      **2.45** (1.56--3.86)                   
                                                                                                                                                        
  rs2421805                           11    T/T  44/130 (33.8)    104/216 (48.1)      **1.93×10**^**−3**^            9.21×10^−3^                    0.0108
                                      12    T/G  65/130 (50.0)    96/216 (44.4)            **0.0348**                   0.166                        0.194
                                      22    G/G  21/130 (16.2)    16/216 (7.41)     **0.602** (0.436--0.831)     0.551 (0.351--0.865)        0.415 (0.208--0.829)
                                                                                                                                                        
  rs7543182                           11    G/G  92/132 (69.7)    112/221 (50.7)          9.29×10^−3^            **4.64×10**^**−4**^                 0.591
                                      12    G/T  29/132 (22.0)    94/221 (42.5)              0.167               **8.36×10**^**−3**^                    
                                      22    T/T  11/132 (8.33)    15/221 (6.79)        1.63 (1.13--2.36)        **2.24** (1.42--3.53)                   
                                                                                                                                                        
  rs.7555874                          11    G/G  91/132 (68.9)    112/221 (50.7)             0.0130              **7.85×10**^**−4**^                 0.591
                                      12    G/A  30/132 (22.7)    94/221 (42.5)              0.234                    **0.0141**                        
                                      22    A/A  11/132 (8.33)    15/221 (6.79)        1.59 (1.10--2.30)        **2.16** (1.37--3.40)                   
                                                                                                                                                        
  rs4147115                           11    A/A  45/128 (35.2)    54/212 (25.5)              0.0603                     0.0569                       0.291
                                      12    A/T  54/128 (42.2)    99/212 (46.7)                                                                         
                                      22    T/T  29/128 (22.7)    59/212 (27.8)                                                                         
                                                                                                                                                        
  rs4650093                           11    C/C  84/132 (63.6)    113/220 (51.4)             0.129                      0.0247                       0.486
                                      12    C/T  37/132 (28.0)    93/220 (42.3)                                         0.445                           
                                      22    T/T  11/132 (8.33)    14/220 (6.36)                                   1.66 (1.06--2.58)                     
                                                                                                                                                        
  rs17131478                          11    G/G  86/131 (65.6)    135/219 (61.6)             0.420                      0.452                        0.613
                                      12    G/T  41/131 (31.3)    75/219 (34.2)                                                                         
                                      22    T/T  4/131 (3.05)     9/219 (4.11)                                                                          
                                                                                                                                                        
  rs17131479                          11    C/C  87/132 (65.9)    135/217 (62.2)             0.485                      0.486                        0.744
                                      12    C/G  41/132 (31.1)    74/217 (34.1)                                                                         
                                      22    G/G  4/132 (3.03)     8/217 (3.69)                                                                          
                                                                                                                                                        
  rs7521005                           11    A/A  84/132 (63.6)    114/221 (51.6)             0.138                      0.0273                       0.479
                                      12    A/G  37/132 (28.0)    93/221 (42.1)                                         0.491                           
                                      22    G/G  11/132 (8.33)    14/221 (6.33)                                   1.64 (1.06--2.56)                     
                                                                                                                                                        
  rs7541092                           11    G/G  86/131 (65.6)    136/218 (62.4)             0.488                      0.540                        0.608
                                      12    G/A  41/131 (31.3)    73/218 (33.5)                                                                         
                                      22    A/A  4/131 (3.05)     9/218 (4.13)                                                                          
                                                                                                                                                        
  rs1327464                           11    G/G  83/131 (63.4)    194/219 (88.6)      **7.92×10**^**−10**^       **1.90×10**^**−8**^          **1.23×10**^**−3**^
                                      12    G/A  40/131 (30.5)    24/219 (11.0)       **1.43×10**^**−8**^        **3.41×10**^**−7**^              **0.0221**
                                      22    A/A  8/131 (6.11)     1/219 (0.457)     **0.232** (0.142--0.381)   **0.223** (0.129--0.385)   **0.0705** (0.00872--0.571)
                                                                                                                                                        
  rs1409161                           11    G/G  57/132 (43.2)    68/221 (30.8)              0.0988                     0.0183                       0.958
                                      12    G/A  52/132 (39.4)    114/221 (51.6)                                        0.329                           
                                      22    A/A  23/132 (17.4)    39/221 (17.6)                                   1.71 (1.09--2.67)                     
                                                                                                                                                        
  rs34885906                          11    T/T  120/132 (90.9)   189/221 (85.5)             0.152                      0.138                         ---
                                      12    T/C  12/132 (9.09)    32/221 (14.5)                                                                         
                                      22    C/C  0/132 (0.00)     0/221 (0.00)                                                                          
                                                                                                                                                        
  rs2817864                           11    T/T  77/132 (58.3)    118/221 (53.4)             0.146                      0.367                       0.0352
                                      12    T/G  53/132 (40.2)    89/221 (40.3)               ---                        ---                         0.634
                                      22    G/G  2/132 (1.52)     14/221 (6.33)               ---                        ---                  4.40 (0.983--19.7)
                                                                                                                                                        
  rs1409981                           11    G/G  37/131 (28.2)    60/218 (27.5)              0.874                      0.884                        0.664
                                      12    G/A  65/131 (49.6)    114/218 (52.3)                                                                        
                                      22    A/A  29/131 (22.1)    44/218 (20.2)                                                                         

  *b. Interaction between HLA-A\*02:06 and PTGER3 rs1327464 GA/AA*                                                          
  ------------------------------------------------------------------ ---- ---------------- ----------------- -------------- -----------------------
  \+                                                                  \+  22/131 (16.8%)   4/218 (1.83%)     2.56×10^−7^    **10.8** (3.63--32.1)
  \+                                                                  −   39/131 (29.8%)   26/218 (11.9%)    3.38×10^−5^    3.13 (1.80--5.45)
  −                                                                   \+  26/131 (19.9%)   21/218 (9.63%)    6.80×10^−3^    2.32 (1.25--4.33)
  −                                                                   −   44/131 (33.6%)   167/218 (76.6%)   1.74×10^−15^   0.154 (0.0956--0.249)

Abbreviations: CI, confidence interval; CM-SJS, cold medicine-related Stevens--Johnson syndrome; OR, odds ratio; SOC, severe ocular complication; SNP, single-nucleotide polymorphism; TEN, toxic epidermal necrolysis.

*P* value for allele or genotype frequency. Comparison was between patients and controls using the chi-square test (Pearson).

Corrected *P*: *P* values corrected for the multiplicity of testing by the number of comparisons (*n*=18).

In table 1a, bold values denote *P* values that are significant after correction for the multiplicity of testing by the number of comparisons. In table 1b, bold value denotes OR with additive effect.

###### Korean CM-SJS/TEN with SOC patients

  *a. Association with PTGER3 SNP*                                                                                            
  ---------------------------------- ---- ----- -------------- ---------------- ---------------------- ---------------------- -----
  rs1327464                          11   G/G   17/30 (56.7)   101/120 (84.2)        **0.00203**            **0.00101**       ---
                                     12   G/A   13/30 (43.3)   19/120 (15.8)     0.311 (0.144--0.673)   0.246 (0.103--0.589)   
                                     22   A/A   0/30 (0.00)    0/120 (0.00)                                                    

  *b. Interaction between HLA-A\*02:06 and PTGER3 rs1327464 GA/AA*                                                       
  ------------------------------------------------------------------ ---- --------------- ---------------- ------------- -----------------------
  \+                                                                  \+  8/30 (26.7%)    3/120 (2.50%)     5.58×10^−6^  **14.2** (3.49--57.7)
  \+                                                                  −   2/30 (6.67%)    17/120 (14.2%)       0.269     0.433 (0.0943--1.99)
  −                                                                   \+  5/30 (16.7%)    16/120 (13.3%)       0.638     1.30 (0.435--3.89)
  −                                                                   −   15/15 (50.0%)   84/120 (70.0%)      0.0386     0.429 (0.190--0.968)

Abbreviations: CI, confidence interval; CM-SJS, cold medicine-related Stevens--Johnson syndrome; OR, odds ratio; SOC, severe ocular complication; SNP, single-nucleotide polymorphism; TEN, toxic epidermal necrolysis.

*P* value for allele or genotype frequency. Comparison was between patients and controls using the chi-square test (Pearson).

In table 1a, bold values denote *P* values that are significant after correction for the multiplicity of testing by the number of comparisons. In table 1b, bold value denotes OR with additive effect.
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